A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R.
Santos JR, et al. Among authors: paredes r.
Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov.
Open Forum Infect Dis. 2023.
PMID: 38023553
Free PMC article.